Eli Lilly and Company (NYSE:LLY) Shares Sold by Stockman Wealth Management Inc.

Stockman Wealth Management Inc. reduced its position in Eli Lilly and Company (NYSE:LLY) by 2.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,254 shares of the company’s stock after selling 53 shares during the period. Stockman Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $1,314,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. Simon Quick Advisors LLC lifted its position in Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after acquiring an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth approximately $363,000. WASHINGTON TRUST Co increased its holdings in Eli Lilly and Company by 16.5% during the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after purchasing an additional 2,671 shares during the last quarter. Liontrust Investment Partners LLP purchased a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $8,326,000. Finally, Assenagon Asset Management S.A. increased its holdings in Eli Lilly and Company by 4.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 474,940 shares of the company’s stock worth $255,105,000 after purchasing an additional 18,079 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

LLY stock traded up $5.01 during trading on Monday, reaching $731.32. 2,352,768 shares of the company’s stock were exchanged, compared to its average volume of 3,064,126. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1-year low of $370.68 and a 1-year high of $800.78. The company’s fifty day moving average price is $763.83 and its 200-day moving average price is $662.78. The firm has a market cap of $694.87 billion, a PE ratio of 126.09, a P/E/G ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the previous year, the firm posted $2.09 EPS. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a report on Wednesday, February 21st. Morgan Stanley lifted their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Finally, Barclays boosted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the sale, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.